Legend Biotech Corporation (LEGN) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Legend Biotech (LEGN) Q1 2026: CARVICTI Ex-U.S. Sales Jump 200% as Early-Line Adoption Accelerates
May 12, 2026
-
Legend Biotech (LEGN) Q4 2025: Carvicti Doses Scale to 10,000 as Early-Line Penetration Accelerates
March 10, 2026
-
Legend Biotech (LEGN) Q3 2025: CARVICTI Sales Up 84% as Capacity Expansion Targets 10,000 Doses
November 12, 2025
-
Legend Biotech (LEGN) Q2 2025: CARVICTI Sales Jump 136%, Expanding Early-Line Adoption and Global Reach
August 11, 2025
-
Legend Biotech (LEGN) Q1 2025: CARVICTI Sales Up 135% as Early-Line Uptake Accelerates
July 07, 2025